Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Inhibition of Pulmonary Fibrosis by the Chemokine IP-10/CXCL10

Tager, Andrew M., Kradin, Richard L., LaCamera, Peter, Bercury, Scott D., Campanella, Gabriele S. V., Leary, Carol P., Polosukhin, Vasiliy, Zhao, Long-Hai, Sakamoto, Hideo, Blackwell, Timothy S., Luster, Andrew D.·2004·American Journal of Respiratory Cell and Molecular Biology

Abstract

Pulmonary fibrosis is an enigmatic and devastating disease with few treatment options, now thought to result from abnormal wound healing in the lung in response to injury. We have previously noted a role for the chemokine interferon gamma-inducible protein of 10 kD (IP-10)/CXC chemokine ligand 10 in the regulation of cutaneous wound healing, and consequently investigated whether IP-10 regulates pulmonary fibrosis. We found that IP-10 is highly expressed in a mouse model of pulmonary fibrosis induced by bleomycin. IP-10-deficient mice exhibited increased pulmonary fibrosis after administration of bleomycin, suggesting that IP-10 limits the development of fibrosis in this model. Substantial fibroblast chemoattractant and proliferative activities were generated in the lung after bleomycin exposure. IP-10 significantly inhibited fibroblast responses to the chemotactic, but not the proliferative activity generated, suggesting that IP-10 may attenuate fibroblast accumulation in bleomycin-induced pulmonary fibrosis by limiting fibroblast migration. Consistent with this inhibitory activity of IP-10 on fibroblast migration, fibroblast accumulation in the lung after bleomycin exposure was dramatically increased in IP-10-deficient mice compared with wild-type mice. Conversely, transgenic mice overexpressing IP-10 were protected from mortality after bleomycin exposure, and demonstrated decreased fibroblast accumulation in the lung after challenge compared with wild-type mice. Our findings suggest that interruption of fibroblast recruitment may represent a novel therapeutic strategy for pulmonary fibrosis, which could have applicability to a wide range of fibrotic illnesses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1165/rcmb.2004-0175oc

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 199

Metadata

Authors
Tager, A. M., Kradin, R. L., LaCamera, P., Bercury, S. D., Campanella, G. S. V., Leary, C. P., Polosukhin, V., Zhao, L.-H., Sakamoto, H., Blackwell, T. S., & Luster, A. D.
Venue
American Journal of Respiratory Cell and Molecular Biology
Published
2004-10
Volume
31
Issue
4
Pages
395-404
ISSN
  • 1044-1549 (ISSN-L)
  • 1535-4989
OpenAlex
W2098765934
Cited by
199
References
3
FWCI
4.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of Pulmonary Fibrosis by the Chemokine IP-10/CXCL10. https://app.cochat.ai/papers/10.1165/rcmb.2004-0175oc
The paper
Tager, A. M., Kradin, R. L., LaCamera, P., Bercury, S. D., Campanella, G. S. V., Leary, C. P., Polosukhin, V., Zhao, L.-H., Sakamoto, H., Blackwell, T. S., & Luster, A. D. (2004). Inhibition of Pulmonary Fibrosis by the Chemokine IP-10/CXCL10. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2004-0175oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.